skitahoe, The beauty of the Direct patent is that it foretells who responding patients will be based on the DC characteristics able to be created during maturation/activation. It really is just that simple. DCs with the right characterization created prior to immunization will be sufficient to overcome cancer defenses. I believe that what they found in Direct Phase 1 also helped them realize how to activate and enlist another set of immune cells even with a more mature state of DCs being utilized in L to create an L plus scenario to compensate for using more mature DCs that are past their prime state for in situ applications. There is a reason why Kat’s Cure worked on her and Mr. Powers and I don’t think it only has to do with advanced tumor heterogeneity. I think Merck is aware of this. Best wishes.
Market Data 
Markets 
AI
